Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, Piruzeli MLB, Goldman JD, Alatorre-Alexander J, de Cassia Pellegrini R, Estrada V, Som M, Cardoso A, Chakladar S, Crowe B, Reis P, Zhang X, Adams DH, Ely EW; COV-BARRIER Study Group.
. Hu X, et al. Environ Sci Technol. 2014 Jun 17;48(12):6919-27. doi: 10.1021/es5012548. Epub 2014 Jun 5. Environ Sci Technol. 2014. PMID: 24857237
. Wightman DP, et al. Nat Genet. 2021 Sep;53(9):1276-1282. doi: 10.1038/s41588-021-00921-z. Epub 2021 Sep 7. Nat Genet. 2021. PMID: 34493870
. Kyriazopoulou E, et al. Nat Med. 2021 Sep 3. doi: 10.1038/s41591-021-01499-z. Online ahead of print. Nat Med. 2021. PMID: 34480127
.
Item in Clipboard